EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access · CC BY 3.0

Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis

Kapil Gudala, Raju Kanukula, Dipika Bansal

International Journal of Chronic Diseases · 2015

DOI: 10.1155/2015/697404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Chronic Diseases, 2015. Verfasst von Kapil Gudala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To pool the data currently available to determine the association between calcium channel blockers (CCBs) and risk of Parkinson’s disease (PD).

Methods

Literature search in PubMed, EBSCO, and Cochrane library was undertaken through March 2014, looking for observational studies evaluating the association between CCBs use and PD. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model. Subgroup analyses, sensitivity Analysis, and cumulative meta-analysis were also performed.

Results

Six studies were included in our meta-analysis according to the selection criteria, including three cohort studies and three case-control studies involving 27,67,990 subjects including 11,941 PD cases. We found CCBs use was associated with significant decreased risk of PD, compared with not using CCBs (random effects model pooled RR, 0.81 (95% CI, 0.69–0.95)); a significant heterogeneity was found between studies ( P = 0.031 ; I 2 54.6%). Both the classes of CCB, that is, dihydropyridine calcium channel blockers (DiCCB) (0.80 (95% CI, 0.65–0.98) P = 0.032 ) and non-DiCCB (0.70 (95% CI, 0.53–0.92) P = 0.013 ), were found to be reducing the risk of PD.

Conclusion

In our analysis, we found that CCBs use was associated with a Significantly decreased risk of PD compared with non-CCB use.

Autor:innen und Institutionen

  • Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India.

Zitieren

APA

Gudala, K., Kanukula, R., & Bansal, D. (2015). Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis. International Journal of Chronic Diseases. https://doi.org/10.1155/2015/697404

Vancouver

Gudala K, Kanukula R, Bansal D. Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis. International Journal of Chronic Diseases. 2015. doi:10.1155/2015/697404

BibTeX
@article{Gudala2015,
  author = {Gudala, Kapil and Kanukula, Raju and Bansal, Dipika},
  title = {Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis},
  journal = {International Journal of Chronic Diseases},
  year = {2015},
  doi = {10.1155/2015/697404}
}
Kostenlos starten →